In summary, this study demonstrates that CXCR4-targeted 18F-AlF-NOTA-pentixafor PET/CT is a valuable noninvasive tool to diagnose UPA with high sensitivity and specificity and to guide further treatment options. This evidence concerns the gene CXCR4 and urokinase-type plasminogen activator measurement.